Drug Injury Watch, published by the Law Offices of Thomas J. Lamb, P.A., focuses on legal and medical information related to adverse effects and injuries caused by prescription drugs. The blog covers topics such as drug recalls, side effects, and emerging drug injury lawsuits involving medications like Andexxa, Wegovy, Ozempic, Dupixent, and Depo-Provera. It provides updates on medical studies linking drugs to specific injuries, FDA actions, and legal claims for compensation. The site emphasizes individual drug injury cases rather than class actions, offering free case evaluations and insights from attorney Tom Lamb based on extensive experience in drug injury litigation.
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis
(Posted by Tom Lamb at Drug Injury Watch)
A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis of…
But the January 2026 Rybelsus-Ozempic Drug Label Still Has No Warnings for NAION Vision Loss Side Effect
(Posted by Tom Lamb at Drug Injury Watch)
The “Revised: 1/2026” Prescribing Information document for “RYBELSUS and OZEMPIC tablets” caused some initial…
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study
(Posted by Tom Lamb at Drug Injury Watch)
This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing drugs (Ozempic, Wegovy,…
Acute Pancreatitis, Including Fatal Hemorrhagic And Necrotizing Pancreatitis – Death Cases
(Posted by Tom Lamb at Drug Injury Watch)
In October 2025, Rybelsus pancreatitis side effects warnings were added to the Rybelsus “drug label”, and in late January 2026…
Women Who Had Depo-Provera Injections Before December 2025 Label Change Can Still Sue Responsible Pharmaceutical Drug Companies
(Posted by Tom Lamb at Drug Injury Watch)
In December 2025, a Depo-Provera “meningioma warning” label change was required by the FDA…
Rybelsus (Semaglutide) Associated With Significantly Increased Risk Of Blood Clots
(Posted by Tom Lamb at Drug Injury Watch)
In this post, we point out a recent medical journal article that discusses a Rybelsus deep vein thrombosis case report. We…
Federal Court MDL: IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
(Posted by Tom Lamb at Drug Injury Watch)
In December 2025, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued…
High Rate Of Thrombotic Events And More Thrombosis-related Deaths Compared To Standard Antidote Treatment
(Posted by Tom Lamb at Drug Injury Watch)
Just about a year ago, we wrote about the possibility of an Andexxa drug recall in this…
Because Semaglutide is Linked to NAION, Wegovy and Ozempic Drug Injury Cases Have Been Filed In the US
(Posted by Tom Lamb at Drug Injury Watch)
Here is what you need to know:
…
Higher Risk Of Meningioma Side Effects Associated With Depo-Provera for These Women, According to a 2025 Medical Study Report
(Posted by Tom Lamb at Drug Injury Watch)
A recent medical study looking at Depo-Provera meningioma cases in the US…
